Used in targeted cancer therapy, particularly for cancers that overexpress MUC1, such as breast, pancreatic, and ovarian cancers. It serves as a reference standard in the development of antibody-drug conjugates (ADCs), helping researchers evaluate binding affinity, specificity, and efficacy of new anti-MUC1 therapeutics. Widely applied in preclinical studies to benchmark diagnostic imaging agents and therapeutic antibodies. Also utilized in flow cytometry, immunohistochemistry, and ELISA to detect MUC1 expression in tumor samples, supporting both research and clinical assay development.